Document is current
Any future updates will be listed below
-
Authors
,
Chimenti, Cristina
Nencini, Patrizia
Pieruzzi, Federico
Feriozzi, Sandro
Mignani, Renzo
Pieroni, Maurizio
Pisani, Antonio
- License Information
-
More Information
Article History
Received: 31 July 2019
Accepted: 28 January 2020
First Online: 7 April 2020
Ethics approval and consent to participate
: Not applicable.
: All the co-authors have read the manuscript and approved its submission to “Orphanet Journal of Rare Diseases”.
: CC has received travel assistance and honoraria for teaching from Shire and Amicus Therapeutics. SF has received travel assistance and honoraria for lecturing and for participating in advisory boards from Genzyme/Sanofi, Shire, Amicus Therapeutics, Otsuka. AP has received travel assistance and honoraria for lecturing and for participating in advisory boards from Genzyme/Sanofi, Shire, Amicus Therapeutics, Protalix. PN has received travel assistance and honoraria for lecturing and for participating in advisory boards from Shire, Genzyme/Sanofi, and Amicus Therapeutics. FP has received travel assistance and honoraria for lecturing and for participating in advisory boards from Sanofi Genzyme, Shire-Takeda and Amicus Therapeutics. RM has received travel assistance and honoraria for lecturing and for participating in advisory boards from Sanofi Genzyme, Takeda, Amicus Therapeutics and Otsuka. MP has received travel assistance and honoraria for lecturing and for participating in advisory boards from Sanofi Genzyme, Takeda, Amicus Therapeutics and Otsuka.
